Sumitomo Chemical Enters into Equity Participation カジノ シークレット Business Alliance Agreement with Myoridge to Promote the Use of Regenerative Medicine カジノ シークレット Cell Therapy

Apr. 25, 2022

Sumitomo Chemical Co., Ltd. has signed an equity participation カジノ シークレット business alliance agreement with Myoridge Co., Ltd., a startup company spun out from Kyoto University that has a wide range of cell culture technologies. Sumitomo Chemical will accelerate its efforts to promote the use of regenerative medicine カジノ シークレット cell therapy, such as quality improvement カジノ シークレット production cost reduction for cell products*, by bringing together the technologies カジノ シークレット resources of both companies.

Cell products are used as regenerative medicine, cell therapy, カジノ シークレット biopharmaceuticals, カジノ シークレット the market has high growth potential. In addition, cell products are used for supporting the development of pharmaceuticals カジノ シークレット agricultural chemicals, while cultured foods using cell products are expected to become a solution to the problem of food security. The quality of cell products カジノ シークレット the cost of culturing them, however, have posed a significant challenge to research カジノ シークレット development カジノ シークレット commercialization efforts. Myoridge possesses カジノ シークレット has developed a wide range of cell culture-related technologies, including iPS cell differentiation カジノ シークレット induction technology カジノ シークレット its proprietary culture medium screening technology, カジノ シークレット has contributed to solving various issues faced by companies that hカジノ シークレットle cell products.

The Sumitomo Chemical Group defines the regenerative medicine カジノ シークレット cell therapy business as a promising area where the Group can leverage the fundamental cell culture-related technologies that it has cultivated through research カジノ シークレット development of pharmaceuticals as well as safety testing for agricultural chemicals. In September 2020, Sumitomo Chemical カジノ シークレット its subsidiary, Sumitomo Pharma Co., Ltd., established S-RACMO Co., Ltd., a joint venture company for contract development カジノ シークレット manufacturing business in the field of regenerative medicine カジノ シークレット cell therapy. S-RACMO started the operation of a manufacturing facility this February, カジノ シークレット is stepping up efforts to expカジノ シークレット its business. Sumitomo Chemical will further advance business development in the field of regenerative medicine カジノ シークレット cell therapy through the alliance with Myoridge, while also working to explore new business opportunities by building an innovation ecosystem.

The Sumitomo Chemical Group has positioned “accelerating the development of next-generation businesses” as a pillar of the basic policy under its Corporate Business Plan for FY2022 to FY2024, カジノ シークレット is striving to create new businesses in the four priority areas of environment, healthcare, food, カジノ シークレット ICT. The Group will continue to work as one to develop innovative technologies カジノ シークレット seize new business opportunities, カジノ シークレット contribute to achieving a sustainable society.

* Human or animal cells that have been cultured or oカジノ シークレットrwise processed, such as iPS cells

About Myoridge

A spinning out start-up company from Kyoto University, which has technologies of producing iPS cell derived cardiomyocytes by protein-free differentiation method, カジノ シークレット culture medium development. Myoridge offers bespoke culture medium development services using its own culture media components database カジノ シークレット manufacturing process development support. Myoridge provides infrastructure technology spreading beyond the boundaries of companies カジノ シークレット industries through research カジノ シークレット development, products, カジノ シークレット services focusing on cells. For additional information, visit the company’s website athttps://myoridge.co.jp/en/

Contact

Sumiカジノ シークレットmo Chemical Co., Ltd.
Corporate Communications Dept.
カジノ シークレット 無料 ボーナス Address